Related Experiment Videos
Fondaparinux sodium
1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Drugs
|July 12, 2002
Summary
Fondaparinux sodium, a novel antithrombotic, effectively prevents venous thromboembolism in major orthopedic surgery patients. This selective factor Xa inhibitor demonstrates optimal efficacy and safety, with a favorable tolerability profile compared to enoxaparin.
Area of Science:
- Pharmacology
- Thrombosis Research
- Orthopedic Surgery
Background:
- Fondaparinux sodium is a new class of antithrombotics.
- It selectively inhibits factor Xa by binding to antithrombin III.
- Its long half-life allows for once-daily administration.
Purpose of the Study:
- To determine the optimal dose of fondaparinux sodium for venous thromboembolism prophylaxis.
- To evaluate the efficacy and safety of fondaparinux sodium compared to enoxaparin.
- To assess the tolerability profile of fondaparinux sodium in orthopedic surgery patients.
Main Methods:
- Phase IIb randomized, double-blind, dose-ranging study in 933 patients.
- Phase III prospective, randomized, double-blind clinical trials involving over 3600 patients.
- Comparison of fondaparinux sodium with enoxaparin for venous thromboembolism prophylaxis.
Main Results:
- A subcutaneous dose of 1.5-3mg of fondaparinux sodium showed optimal efficacy and safety for VTE prophylaxis.
- Fondaparinux sodium significantly reduced VTE incidence by 55.2% compared to enoxaparin.
- Fondaparinux sodium demonstrated a similar tolerability profile to enoxaparin, with no reported antibody-induced thrombocytopenia.
Conclusions:
- Fondaparinux sodium is an effective and safe option for VTE prophylaxis in major orthopedic surgery.
- The recommended dose of 2.5mg offers a favorable balance of efficacy and safety.
- Fondaparinux sodium presents a well-tolerated alternative to existing treatments like enoxaparin.